Amplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%

MT Newswires Live

03/09

Amplia Therapeutics (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of cancer, according to a Monday Australian bourse filing.

Narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, it noted.

The combination led to improved responsiveness to chemotherapy in preclinical models, and narmafotinib combined with pan-RAS inhibitor improves tumor growth inhibition, the company said.

Tumors in ovarian cancer treated with narmafotinib combined with pegylated liposomal doxorubicin reduced KRAS signaling, the company added.

Amplia Therapeutics' shares fell 9% in recent trading on Monday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2618619241"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618619241\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618619241?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 12:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618619241","market":"sh","top_or_hot":-1,"title":"Amplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of cancer, according to a Monday Australian bourse filing.</p><p>Narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, it noted.</p><p>The combination led to improved responsiveness to chemotherapy in preclinical models, and narmafotinib combined with pan-RAS inhibitor improves tumor growth inhibition, the company said.</p><p>Tumors in ovarian cancer treated with narmafotinib combined with pegylated liposomal doxorubicin reduced KRAS signaling, the company added.</p><p>Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' shares fell 9% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-09 12:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of cancer, according to a Monday Australian bourse filing.</p><p>Narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, it noted.</p><p>The combination led to improved responsiveness to chemotherapy in preclinical models, and narmafotinib combined with pan-RAS inhibitor improves tumor growth inhibition, the company said.</p><p>Tumors in ovarian cancer treated with narmafotinib combined with pegylated liposomal doxorubicin reduced KRAS signaling, the company added.</p><p>Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' shares fell 9% in recent trading on Monday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618619241","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618619241","pubTimestamp":1773029208,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of can","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK7067":"生物科技","BK4007":"制药","ATX.AU":"AMPLIA THERAPEUTICS LTD","BK4539":"次新股"},"translate_title":"Amplia Therapeutics表示，临床前数据显示候选药物可增强kRAS抑制剂在癌症治疗中的作用；股价下跌9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATX.AU":1},"content_text":"Amplia Therapeutics (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of cancer, according to a Monday Australian bourse filing.Narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, it noted.The combination led to improved responsiveness to chemotherapy in preclinical models, and narmafotinib combined with pan-RAS inhibitor improves tumor growth inhibition, the company said.Tumors in ovarian cancer treated with narmafotinib combined with pegylated liposomal doxorubicin reduced KRAS signaling, the company added.Amplia Therapeutics' shares fell 9% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}